Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Abnormal Uterine Bleeding in Adolescents Maria C. Monge, MD Director of Adolescent Medicine Dell Children’s Medical Center UTSW-Austin Pediatrics Residency Program Lone Star Circle of Care Disclosures • I have no relevant financial disclosures. Objectives • 1. Define abnormal uterine bleeding (AUB) in an adolescent. • 2. Discuss possible etiologies of AUB in an adolescent and use these in consideration of the the initial outpatient workup of AUB. • 3. Identify initial outpatient management strategies for adolescents with AUB. CASE – MADELINE Madeline • Madeline is a 12 year old who comes to your office after she felt lightheaded at school. – Mom called and triage nurse said to bring her in. – Mom told the nurse that Madeline has had menstrual bleeding for more than 1 week and has been feeling more tired than usual for the past month. Madeline • Review of records before she arrives – Healthy, on no medications – Growth and development normal • 50% BMI • At last WCC had not started menstruating, but had SMR3 breasts and pubic hair – Family history unremarkable NORMAL MENSES Normal Menses • Menarche: 2.3y after pubertal initiation – Range 1-3 years • Cycle length: 21-42 days (beginning to beginning) – Should be regular by 2-2.5 years – Cycles outside of 20-45 days should be considered abnormal even in adolescents • Duration: 3-7 days • Average blood loss: 30 mL/cycle – Can be 20-80mL Normal Menses Anovulatory Cycles • 55-82% of adolescents take up to 24 months after menarche before having regular ovulatory cycles – Adolescents with later onset of menarche have longer intervals until cycles become ovulatory – Immaturity of HPO axis • Having an occasional ovulatory cycle stabilizes endometrial growth and allows for complete shedding Madeline • On arrival to office -- History – In the midst of her 3rd menstrual period • First one about 4 months ago and was light, lasted 5 days; Second one about 2 months ago and was moderate flow lasting 7 days – Started 8 days prior – Soaking pads every 1-2 hours How do you quantify bleeding? • Proposed screening questions – Period lasting > 7 days – Feeling of “flooding” or “gushing” most cycles – Activities limited by periods – Bleeding “problem” after dental extraction, surgery or delivery/miscarriage – Family history of bleeding disorder Madeline – Additional details • ROS: feeling tired, maybe easy bruising but not sure, no acne or hirsuitism • Medications: None • Family History: Mom menarche age 13 and was irregular for 1-2 years • Social history: Lives with Mom, in 6th grade, has a boyfriend but no sex, no trauma, no foreign bodies in vagina DIFFERENTIAL DIAGNOSIS Differential for abnormal bleeding • Anovulatory uterine bleeding • Endocrine disorders • Bleeding disorders • Pregnancy-related complications • Infection • Hormonal contraception • Use of IUDs • Medications • Vaginal, cervical or uterine carcinoma, sarcoma, polyps • Cervical hemangioma • Congenital uterine abnormalities • Vaginal lacerations, trauma • Endometriosis • Foreign body What is on our differential for Madeline? • Systematic approach • Consider pertinent history and physical What is on our differential for Madeline? • Systematic approach – Prolactinoma – Thyroid Disease – Cushings, CAH – PCOS, Anovluation, Pregnancy, POI, Trauma, Infection, Polyp – Bleeding Disorder EXAM CONSIDERATIONS Exam • Key points – Vitals , Height, Weight, BMI – Features of endocrinopathies • Androgen excess • Cushingoid • Thyroid – Other signs of bleeding – GU exam • Minimum is external • Pelvic exam-most girls who have used tampons can tolerate a 1 finger digital exam to check for foreign bodies Madeline - Exam • • • • • • • Vital Signs: BP 98/66 HR 72 T 98.4 BMI 75th% Gen: slightly pale and anxious-appearing Neck: no thyroid enlargement CV: soft SEM at RUSB Chest: SMR4 breast Abd: soft, NT/ND, no striae GU: SMR 4 pubic hair, external exam without evidence of trauma, +bleeding from vagina • Skin: no hirsuitism, acne, acanthosis, petechiae, bruising Any changes to the differential? • Anything move up or down the list? LABORATORY EVALUATION Laboratory Evaluation • • • • • • • CBC with differential B-hcg (sensitive urine or serum) TSH, free T4 Type and Screen FSH, LH, prolactin, free/total T, DHEA-S PT/PTT, von Willebrand panel GC/CT testing Madeline - Results • CBC: Hemoglobin 10.4 g/dL, remainder normal • Urine hcg: negative • TSH: 255 mIU/L, T4 0.5 mcg/L • Von Willebrand Panel: – VW Factor 90% (50-160 normal) – Factor XIII 142% (70-170 normal) A note about VWF screening • Many factors impact VWF levels – Ideal to test off of hormones or on Day 7 of placebos • VWD <30% activity now considered diagnostic – 30-50% is “low von Willebrand factor” • Consider screening as not uncommon in adolescents with menorrhagia – Estimates vary widely in literature with many suffering from selection bias Role of imaging? • Consider if: – Unable to do pelvic exam – Prolonged bleeding despite treatment – Pelvic mass or uterine anomaly suspected Next steps? • Stop bleeding • Treat underlying condition (if applicable) Key points for all patients • All patients should keep a menstrual calendar • Ensure iron stores are addressed, even if Hgb normal. – Patients typically need several months of oral iron to replete stores HORMONAL TREATMENT OF BLEEDING Recommended choice of OCPs • Off-label use • Monophasic • Potent progestin – Norgestrel (0.3mg) • Ex. Lo/Ovral, Low-Ogestrel, Cryselle – Levonorgestrel (0.15mg) • Ex. Nordette, Levlen, Levora, Portia Note: Naming brand names does not imply endorsement of a particular product Treatment depends on current bleeding and Hgb • Mild – Menses slightly prolonged or cycle slightly more frequent – Normal hemoglobin • This can be distressing to patients and families • May observe for several cycles – Iron supplementation – Naproxen or Ibuprofen • Anti-prostaglandins have been reported to decrease blood loss • May consider treatment with OCP or progestin Treatment depends on current bleeding and Hgb • Moderate – Menses >7d or cycle frequency <3 weeks and mild anemia (Hgb 10-11g/dL) • If patient not bleeding significantly at time of visit and is not already on hormonal therapy can start with 1 pill daily • If patient with moderate bleeding at time of visit, 1 pill BID until bleeding stops, then daily for total of 21 days – Continue cyclic pills or may do continuous • Follow Hgb as needed – Consider continuing pills at least until Hgb normal (min 3-6 months) Treatment depends on current bleeding and Hgb • Severe – Ongoing heavy bleeding with moderate anemia (Hgb 8-10g/dL) • If bleeding is slowing and Hgb >9 g/dL – Can start with BID pills (see moderate) • If bleeding not slowing – 1 pill q6h for 2-4 days • prn anti-emetic 2h before pill – 1 pill q8hx 3 days – 1 pill q12h for at least 2 weeks • Follow serial Hgb closely • Consider inpatient admission if concern for patient/family reliability Treatment depends on current bleeding and Hgb • Severe – Ongoing heavy bleeding, Hgb ≤ 7g/dL, Orthostatic vital signs – Admit for inpatient management – Notes • Decision to transfuse not based solely on number • Most patients can be managed with OCPs • D&C rarely indicated What if patient has contraindication to estrogen? • Medroxyprogesterone – Short courses in mild bleeding – Cyclic therapy if need ongoing • Norethindrone acetate – Short courses in mild bleeding – Cyclic therapy – Continuous menstrual suppression • LNG-IUS INDICATIONS FOR REFERRAL When should referral be considered? • To ER – Symptomatic anemia – Vital sign abnormalities • To Adolescent Medicine/Reproductive Endocrinology – OCP complications or decisions – Bleeding difficult to control (breaking through) – Secondary cause identified TAKE HOME POINTS Conclusions • Remember what is “normal” • Differential broad • History is important – Menstrual history as a “vital sign” • CBC to guide treatment • Different treatment options exist Thank you! Contact information: Maria C. Monge, MD Director of Adolescent Medicine UTSW-Austin Pediatrics Residency Program 312-498-3470 [email protected]